http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
The importance of KRAS status in managing metastatic colorectal cancer
Leong, S.; Eckhardt, S. G.; Jimeno, A.; Messersmith, W. Springer Science + Business Media 2009 p.129-134
Evolving end points for clinical trials in advanced colorectal cancer
Gill, S.; Sargent, D. J. Springer Science + Business Media 2009 p.135-139
Harris, S. L.; Tepper, J. E. Springer Science + Business Media 2009 p.140-147
Vergo, M.; Nimeiri, H.; Benson, A. B. Springer Science + Business Media 2009 p.151-157
Risk assessment and adjuvant systemic therapy in resected stage II colon cancer
Shankaran, V.; Khrizman, P.; Benson, A. B. Springer Science + Business Media 2009 p.158-165
Similarities and differences between the adjuvant oxaliplatin-based trials MOSAIC and NSABP C-07
Boni, C.; André, T.; Banzi, M. C.; Hickish, T.; Tabernero, J.; Clingan, P.; Chibaudel, B.; Gramont, A. Springer Science + Business Media 2009 p.166-170
Incidence of KRAS status in ongoing adjuvant trials in colon cancer
Taieb, J.; Laurent-Puig, P.; Alberts, S. Springer Science + Business Media 2009 p.171-178